Morgan Stanley’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.43M | Sell |
1,840,461
-570,079
| -24% | -$1.02M | ﹤0.01% | 4632 |
|
|
2025
Q4 | $4.51M | Buy |
2,410,540
+1,959,325
| +434% | +$3.77M | ﹤0.01% | 4253 |
|
|
2025
Q3 | $578K | Sell |
451,215
-380,555
| -46% | -$515K | ﹤0.01% | 5443 |
|
|
2025
Q2 | $1.03M | Sell |
831,770
-2,539,962
| -75% | -$2.93M | ﹤0.01% | 5079 |
|
|
2025
Q1 | $3.98M | Sell |
3,371,732
-2,279,826
| -40% | -$3.5M | ﹤0.01% | 4119 |
|
|
2024
Q4 | $10.3M | Buy |
5,651,558
+1,759,016
| +45% | +$3.43M | ﹤0.01% | 3378 |
|
|
2024
Q3 | $6.62M | Buy |
3,892,542
+812,786
| +26% | +$1.34M | ﹤0.01% | 3739 |
|
|
2024
Q2 | $4.22M | Buy |
3,079,756
+1,176,905
| +62% | +$2.38M | ﹤0.01% | 4025 |
|
|
2024
Q1 | $7.14M | Sell |
1,902,851
-20,316,313
| -91% | -$119M | ﹤0.01% | 3613 |
|
|
2023
Q4 | $218M | Buy |
22,219,164
+19,933,963
| +872% | +$163M | 0.01% | 1101 |
|
|
2023
Q3 | $19.1M | Buy |
2,285,201
+549,604
| +32% | +$6.28M | ﹤0.01% | 2503 |
|
|
2023
Q2 | $23.1M | Sell |
1,735,597
-318,931
| -16% | -$3.88M | ﹤0.01% | 2333 |
|
|
2023
Q1 | $23.8M | Buy |
2,054,528
+773,836
| +60% | +$7.69M | ﹤0.01% | 2230 |
|
|
2022
Q4 | $10.5M | Sell |
1,280,692
-1,294,188
| -50% | -$11.2M | ﹤0.01% | 3039 |
|
|
2022
Q3 | $14.9M | Sell |
2,574,880
-641,686
| -20% | -$3.68M | ﹤0.01% | 2524 |
|
|
2022
Q2 | $14.2M | Buy |
3,216,566
+1,267,924
| +65% | +$7.7M | ﹤0.01% | 2670 |
|
|
2022
Q1 | $17.7M | Buy |
1,948,642
+840,967
| +76% | +$9.68M | ﹤0.01% | 2246 |
|
|
2021
Q4 | $22.7M | Sell |
1,107,675
-438,882
| -28% | -$10.6M | ﹤0.01% | 2022 |
|
|
2021
Q3 | $39.5M | Buy |
1,546,557
+604,726
| +64% | +$17.9M | 0.01% | 1460 |
|
|
2021
Q2 | $32.9M | Buy |
941,831
+85,278
| +10% | +$2.48M | ﹤0.01% | 1653 |
|
|
2021
Q1 | $28.5M | Buy |
856,553
+340,371
| +66% | +$11.9M | ﹤0.01% | 1597 |
|
|
2020
Q4 | $13.4M | Buy |
516,182
+308,103
| +148% | +$5.24M | ﹤0.01% | 2211 |
|
|
2020
Q3 | $2.05M | Sell |
208,079
-1,073,575
| -84% | -$6.18M | ﹤0.01% | 3633 |
|
|
2020
Q2 | $4.42M | Buy |
1,281,654
+1,157,197
| +930% | +$3.94M | ﹤0.01% | 2800 |
|
|
2020
Q1 | $381K | Sell |
124,457
-1,450,061
| -92% | -$5.94M | ﹤0.01% | 4537 |
|
|
2019
Q4 | $8.09M | Buy |
1,574,518
+684,917
| +77% | +$3.48M | ﹤0.01% | 2660 |
|
|
2019
Q3 | $4.59M | Buy |
889,601
+448,151
| +102% | +$2.51M | ﹤0.01% | 2957 |
|
|
2019
Q2 | $2.67M | Buy |
441,450
+215,976
| +96% | +$1.51M | ﹤0.01% | 3540 |
|
|
2019
Q1 | $1.63M | Sell |
225,474
-80,464
| -26% | -$582K | ﹤0.01% | 3750 |
|
|
2018
Q4 | $2.26M | Buy |
305,938
+73,283
| +31% | +$464K | ﹤0.01% | 3660 |
|
|
2018
Q3 | $1.26M | Sell |
232,655
-66,420
| -22% | -$285K | ﹤0.01% | 4356 |
|
|
2018
Q2 | $1.06M | Buy |
299,075
+19,954
| +7% | +$55.4K | ﹤0.01% | 4598 |
|
|
2018
Q1 | $573K | Buy |
279,121
+30,269
| +12% | +$78.6K | ﹤0.01% | 4925 |
|
|
2017
Q4 | $657K | Buy |
248,852
+76,594
| +44% | +$268K | ﹤0.01% | 4820 |
|
|
2017
Q3 | $904K | Buy |
172,258
+70,285
| +69% | +$302K | ﹤0.01% | 4497 |
|
|
2017
Q2 | $363K | Sell |
101,973
-671,546
| -87% | -$2.71M | ﹤0.01% | 4995 |
|
|
2017
Q1 | $4M | Buy |
773,519
+435,774
| +129% | +$2.13M | ﹤0.01% | 3099 |
|
|
2016
Q4 | $1.28M | Buy |
337,745
+281,224
| +498% | +$2.04M | ﹤0.01% | 4276 |
|
|
2016
Q3 | $507K | Sell |
56,521
-61,363
| -52% | -$513K | ﹤0.01% | 4515 |
|
|
2016
Q2 | $828K | Buy |
117,884
+24,898
| +27% | +$227K | ﹤0.01% | 4117 |
|
|
2016
Q1 | $791K | Sell |
92,986
-284,163
| -75% | -$2.79M | ﹤0.01% | 4132 |
|
|
2015
Q4 | $4.95M | Buy |
377,149
+358,072
| +1,877% | +$3.21M | ﹤0.01% | 2669 |
|
|
2015
Q3 | $70K | Buy |
19,077
+4,955
| +35% | +$24.2K | ﹤0.01% | 5594 |
|
|
2015
Q2 | $81K | Buy |
14,122
+1,264
| +10% | +$7.31K | ﹤0.01% | 5689 |
|
|
2015
Q1 | $75K | Sell |
12,858
-43,217
| -77% | -$298K | ﹤0.01% | 5644 |
|
|
2014
Q4 | $440K | Buy |
56,075
+31,062
| +124% | +$199K | ﹤0.01% | 4755 |
|
|
2014
Q3 | $123K | Buy |
25,013
+1,091
| +5% | +$5.71K | ﹤0.01% | 5376 |
|
|
2014
Q2 | $148K | Sell |
23,922
-329,528
| -93% | -$1.65M | ﹤0.01% | 5305 |
|
|
2014
Q1 | $1.89M | Buy |
353,450
+63,622
| +22% | +$402K | ﹤0.01% | 3471 |
|
|
2013
Q4 | $1.52M | Buy |
289,828
+211,936
| +272% | +$973K | ﹤0.01% | 3595 |
|
|
2013
Q3 | $430K | Buy |
77,892
+61,478
| +375% | +$213K | ﹤0.01% | 4434 |
|
|
2013
Q2 | $42K | Buy |
+16,414
| New | +$40.9K | ﹤0.01% | 5217 |
|
Other funds holding PACB
AIM
VCM
NAMA
Morgan Stanley's PACB Position: Q1 2026 in Review
Morgan Stanley reduced its Pacific Biosciences (PACB) stake by 24% in Q1 2026, selling an estimated $1.02M and leaving 1,840,461 shares worth $2.43M. The position accounts for ﹤0.01% of the portfolio, ranked #4632.
Morgan Stanley first reported a position in PACB in Q2 2013 and has held it in 52 quarters since. The position peaked at $218M in Q4 2023. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.
- Morgan Stanley held 1,840,461 shares of Pacific Biosciences worth $2.43M as of Q1 2026.
- Morgan Stanley sold 570,079 Pacific Biosciences shares in Q1 2026, an estimated $1.02M.
- Pacific Biosciences made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #4632 holding.
- Morgan Stanley first reported a position in Pacific Biosciences in Q2 2013 and has held it in 52 quarters since.
- Morgan Stanley's Pacific Biosciences position peaked at $218M in Q4 2023.
- 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.